Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Propulsion of Acute Lymphocytic Leukemia Pipeline as Novel and Extensive 160+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Published

on

<!– Name:DistributionId Value:8798627 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:678012dd-2084-4cea-aef2-84b563ea005c –>

New York, USA, March 30, 2023 (GLOBE NEWSWIRE) — Propulsion of Acute Lymphocytic Leukemia Pipeline as Novel and Extensive 160+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

The prevalence of acute lymphocytic leukemia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Acute Lymphocytic Leukemia and the growing research and development activities to develop novel therapies to treat acute lymphocytic leukemia to drive the market. The companies developing the potential therapies in the last stage of development include Juventas Cell Therapy, AbbVie, Janssen Biotech, and several others.

DelveInsight’s Acute Lymphocytic Leukemia Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline acute lymphocytic leukemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the acute lymphocytic leukemia pipeline domain.

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

  • DelveInsight’s acute lymphocytic leukemia pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for acute lymphocytic leukemia treatment. 
  • Key acute lymphocytic leukemia companies such as PersonGen BioTherapeutics, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Orca Biosystems, Inc., Sanofi, Beijing Immunochina Medical Science & Technology Co., Ltd., Actinium Pharmaceuticals, Nanjing Bioheng Biotech Co., Ltd., Legend Biotech, Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Kymera Therapeutics, PeproMene Bio, Inc., Takeda Oncology, OneChain Immunotherapeutics, JW Therapeutics, Jazz Pharmaceuticals, Novartis, BRL Medicine, Meryx, Inc.,  Syndax Pharmaceuticals, Janssen Research & Development, LLC, Daiichi Sankyo Company, SecuraBio, Fate Therapeutics, In8bio Inc.,  Newave Pharmaceutical Inc, AstraZeneca,  Biomea Fusion Inc., Karyopharm Therapeutics Inc, Nkarta Inc., Athenex, Inc., ERYtech Pharma, Chongqing Precision Biotech Co., Ltd, Incyte Corporation, BioLineRx, Ltd, OSE Immunotherapeutics, Aleta Biotherapeutics, CalciMedica, Inc., Cabaletta Bio, Hebei Senlang Biotechnology, and others are evaluating new acute lymphocytic leukemia drugs to improve the treatment landscape.
  • Promising acute lymphocytic leukemia pipeline therapies such as CD7 CAR-T cells infusion, TBI-1501, UCART22, Navitoclax, AUTO1, CNCT19, Orca-T, SAR443579, IM19 CAR-T cells, 131-I Apamistamab, CTA30X, CT-RD06, LCAR-AIO Cells, GNC-038, KT-253, BAFFR-CAR T cells, Pevonedistat, OC-1, OC-2, Carteyva, CPX-351, ABL001,  BRL 301, MRX-2843, PIT565, SNDX-5613, JNJ-75276617, AC220, Duvelisib, FT819, EAGD T-cell infusion, LP-108, AZD4573, LP-118, BMF-219, KPT-330, NKX019, KUR-502,  GRASPA, pCAR-19B cells, Ruxolitinib, BL-8040,  OSE-127, WU CART 007, ALETA 001, CM4620,  CT120, CD123, SENL-B-19, SENL 101, HY004,  and others are under different phases of acute lymphocytic leukemia clinical trials.
  • In February 2023, OSE Immunotherapeutics SA announced the online publication in the peer-reviewed ‘The Journal of Immunology’ of positive Phase I clinical results with OSE-127/S95011, an anti-IL-7 receptor (IL-7R) antagonist, and provides an overall update on the product, which is being developed in immuno-inflammation through two ongoing Phase II clinical trials in Ulcerative Colitis (sponsor OSE) and in primary Sjögren’s Syndrome (sponsor Servier), and in hematology where promising preclinical data in Acute Lymphoblastic Leukemia (ALL) has already been reported.OSE-127 has also demonstrated great therapeutic potential in Acute Lymphoblastic Leukemia (ALL), a very aggressive tumor arising from B or T cell precursors. 
  • In December 2022, Juventas Cell Therapy, announced that Inaticabtagene Autoleucel (CNCT19 Injection) has been granted Priority Review Status by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to the New Drug Application (NDA) acceptance, for the treatment of adult relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
  • In December 2022, Juventas Cell Therapy, announced that the National Medical Product Administration (NMPA) of China has accepted the New Drug Application (NDA) of Inaticabtagene Autoleucel (CNCT19 Injection) for the treatment of adult relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
  • In July 2022, the FDA granted fast-track and rare pediatric disease designations to the CAR T-cell therapy WU-CART-007 for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and lymphoblastic lymphoma (LBL).WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR T-cell therapy. The product is designed to overcome the technological challenges of harnessing CAR-T cells to treat CD7-positive hematological malignancies.
  • In May 2022, The FDA granted regenerative medicine advanced therapy designation to obecabatagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Obecabatagene autoleucel also referred to as obe-cel, is an autologous, gene-edited chimeric antigen receptor T-cell therapy that targets the CD19 protein on the surface of cancer cells.
  • In November 2021, Autolus Therapeutics plc and Blackstone Life Sciences announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone will provide up to $250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of obe-cel in B-cell malignancies.

Request a sample and discover the recent advances in acute lymphocytic leukemia treatment drugs @ Acute Lymphocytic Leukemia Pipeline Report

The acute lymphocytic leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage acute lymphocytic leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the acute lymphocytic leukemia clinical trial landscape.

Acute Lymphocytic Leukemia Overview

Acute lymphocytic leukemia (ALL) is also known as acute lymphoblastic leukemia. ALL begins in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most leukemia cells invade the blood fairly quickly. They can also spread to other body parts, such as the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can begin in these organs and spread to the bone marrow, but these are not leukemia.

The early signs and acute lymphocytic leukemia symptoms may resemble those of the flu or other common diseases. Some common signs and acute lymphocytic leukemia symptoms are weakness or tiredness, fever or drenching night sweats, easy bruising or bleeding, shortness of breath, weight loss or loss of appetite, and others.

The tests used for acute lymphocytic leukemia diagnosis include physical exam and health history, complete blood count (CBC) with differential, bone marrow aspiration, and biopsy. The standard goal of acute lymphocytic leukemia includes chemotherapy, radiation therapy, chemotherapy with stem cell transplant, and targeted therapy.

Find out more about acute lymphocytic leukemia treatment drugs @ Drugs for Acute Lymphocytic Leukemia Treatment

A snapshot of the Acute Lymphocytic Leukemia Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
Inaticabtagene autoleucel  Juventas Cell Therapy/CASI Pharmaceuticals Registered Immunologic cytotoxicity; T lymphocyte replacements Intravenous
Venetoclax AbbVie Phase III Proto-oncogene protein c-bcl-2 inhibitors Oral
CPX-351 Jazz Pharmaceuticals Phase II Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors Intravenous
Obecabtagene autoleucel  Autolus Phase I/II Immunologic cytotoxicity; T lymphocyte replacements NA
Navitoclax AbbVie Phase I/II Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors Oral
UCART22 Cellectis Phase I Immunologic cytotoxicity; T lymphocyte replacements Intravenous

Learn more about the emerging acute lymphocytic leukemia pipeline therapies @ Acute Lymphocytic Leukemia Clinical Trials

Acute Lymphocytic Leukemia Therapeutics Assessment

The acute lymphocytic leukemia pipeline report proffers an integral view of the acute lymphocytic leukemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Acute Lymphocytic Leukemia Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
  • Therapeutics Assessment By Molecule Type: Gene therapies, Small molecule, Vaccines, Polymers, Peptides, Monoclonal antibodies
  • Therapeutics Assessment By Mechanism of Action: Antimetabolites, DNA intercalators, DNA synthesis inhibitors, Type II DNA topoisomerase inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors
  • Key Acute Lymphocytic Leukemia Companies: PersonGen BioTherapeutics, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Orca Biosystems, Inc., Sanofi, Beijing Immunochina Medical Science & Technology Co., Ltd., Actinium Pharmaceuticals, Nanjing Bioheng Biotech Co., Ltd., Legend Biotech, Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Kymera Therapeutics, PeproMene Bio, Inc., Takeda Oncology, OneChain Immunotherapeutics, JW Therapeutics, Jazz Pharmaceuticals, Novartis, BRL Medicine, Meryx, Inc.,  Syndax Pharmaceuticals, Janssen Research & Development, LLC, Daiichi Sankyo Company, SecuraBio, Fate Therapeutics, In8bio Inc.,  Newave Pharmaceutical Inc, AstraZeneca,  Biomea Fusion Inc., Karyopharm Therapeutics Inc, Nkarta Inc., Athenex, Inc., ERYtech Pharma, Chongqing Precision Biotech Co., Ltd, Incyte Corporation, BioLineRx, Ltd, OSE Immunotherapeutics, Aleta Biotherapeutics, CalciMedica, Inc., Cabaletta Bio, Hebei Senlang Biotechnology, and others
  • Key Acute Lymphocytic Leukemia Pipeline Therapies: CD7 CAR-T cells infusion, TBI-1501, UCART22, Navitoclax, AUTO1, CNCT19, Orca-T, SAR443579, IM19 CAR-T cells, 131-I Apamistamab, CTA30X, CT-RD06, LCAR-AIO Cells, GNC-038, KT-253, BAFFR-CAR T cells, Pevonedistat, OC-1, OC-2, Carteyva, CPX-351, ABL001,  BRL 301, MRX-2843, PIT565, SNDX-5613, JNJ-75276617, AC220, Duvelisib, FT819, EAGD T-cell infusion, LP-108, AZD4573, LP-118, BMF-219, KPT-330, NKX019, KUR-502,  GRASPA, pCAR-19B cells, Ruxolitinib, BL-8040,  OSE-127, WU CART 007, ALETA 001, CM4620,  CT120, CD123, SENL-B-19, SENL 101, HY004, and others

Dive deep into rich insights for new drugs for acute lymphocytic leukemia treatment, visit @ Acute Lymphocytic Leukemia Drugs

Table of Contents

1. Acute Lymphocytic Leukemia Pipeline Report Introduction
2. Acute Lymphocytic Leukemia Pipeline Report Executive Summary
3. Acute Lymphocytic Leukemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acute Lymphocytic Leukemia Clinical Trial Therapeutics
6. Acute Lymphocytic Leukemia Pipeline: Late Stage Products (Registered)
6.1. Inaticabtagene autoleucel : Juventas Cell Therapy
7. Acute Lymphocytic Leukemia Pipeline: Late Stage Products (Phase III)
7.1. Venetoclax: AbbVie
8. Acute Lymphocytic Leukemia Pipeline: Mid Stage Products (Phase II)
8.1. CPX-351: Jazz Pharmaceuticals
9. Acute Lymphocytic Leukemia Pipeline: Early Stage Products (Phase I)
9.1. UCART22: Cellectis S.A.
10. Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment
11. Inactive Products in the Acute Lymphocytic Leukemia Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Acute Lymphocytic Leukemia Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Acute Lymphocytic Leukemia pipeline therapeutics, reach out @ Acute Lymphocytic Leukemia Treatment Drugs

Related Reports

Acute Lymphocytic Leukemia Epidemiology

Acute Lymphocytic Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted acute lymphocytic leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Lymphocytic Leukemia Market

Acute Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute lymphocytic leukemia companies, including AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, among others.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Acute Myeloid Leukemia Pipeline

Acute Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.

Chronic Lymphocytic Leukemia Pipeline

Chronic Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lymphocytic leukemia companies, including Celgene, Loxo Oncology, Octapharma, among others.

Chronic Myeloid Leukemia Pipeline

Chronic Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic myeloid leukemia companies, including Kartos Therapeutics, Novartis, Incyte Corporation, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market 

Related Healthcare Blogs 

Upcoming Oncology Drugs

Oncology Market Outlook

Future of Oncology Market

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Congregating in the Lion City for a Win-Win Future of Intelligent Computing at the Global Data Center Facility Summit 2024

Published

on

congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024

SINGAPORE, May 17, 2024 /PRNewswire/ — On May 17, 2024, the Global Data Center Facility Summit 2024 was held in Singapore with the theme of “Power the Digital Era Forward.” At the summit, over 600 data center industry leaders, technical experts, and ecosystem partners gathered to discuss new trends and opportunities of the global data center industry in the intelligent computing era. The attendees also got to experience all-scenario, all-ecosystem, and all-service end-to-end (E2E) solutions, share innovative practices of green data centers in the Asia Pacific and Europe, and experience the exhibition vehicle to unveil the mystery of Outdoor PowerPOD that features one power system per container. By fully embracing the intelligent computing era, Huawei strives to power the digital era forward.

Seizing Opportunities Brought by AI and Jointly Building Green & Reliable Computing Infrastructure
At the opening speech, Charles Yang, Senior Vice President of Huawei and President of Marketing, Sales and Services, Huawei Digital Power, noted that since ChatGPT ushered in the AI era, large models keep pushing the limits of computing power and the intelligent computing industry is witnessing an unprecedented construction boom. As predicted, 100 GW will be added to the global data center installed capacity and the market value will exceed US$600 billion in the next five years.
According to Charles, with opportunities come challenges. The primary challenge concerning the data center industry is reliability and electricity. Data centers are scaling up from the MW-level to the GW-level. E2E reliability of data centers is becoming even more important than ever. In response to the opportunities, Huawei will work with customers and partners to expand the industry space.
Steering Data Centers to the AI Era with Product + Service + Ecosystem
During the summit, Sun Xiaofeng, President of Huawei Data Center Facility & Critical Power Business, delivered a speech titled “Power the Digital Era Forward. ” He stated that as AI large models are penetrating, the surging compute demands drive the expansive growth in data center.
To address the challenges, Huawei strives to build product + service + ecosystem E2E data center solutions that feature fast deployment, flexible cooling, green energy, and ultimate reliability.
Fast deployment: Data centers are fully modularized and prefabricated to ensure high quality and efficient construction.Flexible cooling: Air-liquid fusion and integrated cooling source emerges as the optimal cooling architecture for intelligent computing.Green energy: New generation-grid-load-storage integrated solution is built to ensure the sound operations of intelligent computing centers.Ultimate reliability: Data centers are safeguarded through reliable products and preventive protection.Currently, Huawei’s global service network covers more than 170 countries with over 1800 professional engineers, providing 24/7 technical support. With N+ flagship service centers, Huawei has built a one-hour service radius for its customers.
The ecosystem is a key part for a win-win future of intelligent computing. Huawei works with partners to develop comprehensive E2E solutions and provide customers with one-stop data center services.
During the summit, Huawei and the ASEAN Centre for Energy released a white paper on “Building Next Generation Data Center Facility in ASEAN.” The document provides insights into the status quo, challenges, and trends of data centers in the ASEAN region, and emphasizes that efficient and energy-saving products and solutions should be applied. It also proposes future-oriented policy recommendations for data center markets.
In the ecosystem exhibition area, Huawei showcased scenario-based solutions for large-, medium-, and small-sized data centers, and demonstrated data center consulting, design, integrated development, and delivery capabilities with dozens of ecosystem partners including CIMC, Weichai, CSCEC, and Huashi.
On a special note, the Huawei Outdoor PowerPOD exhibition vehicle made its global debut. The Huawei Outdoor PowerPOD features one power system per container, outdoor deployment, plug-and-play, and high protection rating and reliability. It has become the preferred choice for decoupling the power supply architecture.
A single tree cannot make a forest.
AI is presenting great opportunities. By delving into the industry, aggregating partner ecosystems, and making innovations applicable to transformations, Huawei will continue to help customers build reliable computing infrastructure, accelerating the industry to embrace AI and powering the digital era forward.
Photo – https://mma.prnewswire.com/media/2415818/Global_Data_Center_Facility_Summit_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024-302148973.html

Continue Reading

Artificial Intelligence

HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market

Published

on

hoya-group-company,-pentax-of-america,-inc-and-magentiq-eye-ltd-announce-their-intention-to-form-a-distribution-partnership-for-the-u.s-market

WASHINGTON D.C., May 17, 2024 /PRNewswire/ — HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical) and MAGENTIQ-EYE Ltd., an AI medical device company, announced today their intention to form a partnership in the field of AI in Gastroenterology and to examine further collaboration and strategic partnerships.

Pending field trials and customer demonstrations to be conducted over the next several months, the companies expect to formalize an agreement as a first step in this partnership, by which PENTAX Medical will distribute the MAGENTIQ-COLO™ AI-assisted lesion detection device in the U.S.A. beginning October 1st, 2024. The system will be demonstrated at the upcoming Digestive Disease Week (DDW) in Washington D.C., U.S.A.
MAGENTIQ-COLO™ is a cutting-edge system for the detection of gastrointestinal lesions in colonoscopies. Successfully validated in an international multicenter, randomized, controlled trial (RCT) with 950 enrolled patients at 10 hospitals in Europe, United States and Israel, its outstanding diagnostic capabilities are setting new standards in endoscopic AI.
“We are excited to bring the MAGENTIQ-COLO™ device to the GI community in the U.S. Together with PENTAX Medical’s product portfolio, we are confident to provide a smart solution in colonoscopy and contribute further to colorectal cancer prevention”, says David Harrison, President PENTAX of America, Inc.
“Partnering with PENTAX Medical is an important milestone for us, as it opens new opportunities to introduce our game changing product to the U.S. market, benefiting doctors and their patients and saving more lives”, says Dror Zur, Founder & CEO of MAGENTIQ-EYE.
About MAGENTIQ-EYE Ltd.Founded in 2014, MAGENTIQ-EYE offers a groundbreaking AI-aided colonoscopy solution that offers one of the best performances known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy, and saving more and more lives. www.magentiq.com 
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company’s mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. PENTAX Medical strives to align with the healthcare community’s Triple Aim goals through transparent partnerships with its customers and by providing the highest quality solutions to help them reach their goals, including enabling customers to improve patient outcomes by offering evidence-based solutions across the continuum of care; ensuring value by supporting the customers to improve their efficiency and minimize their healthcare costs; and enriching patient and provider’s experience by empowering every member of the care team to achieve optimal outcomes through products, education, and support. Focused on the outcome instead of technological features, PENTAX Medical listens to the healthcare community and their patients, understands their daily obstacles and helps improve endoscopy with smart innovations.
For more information: https://www.pentaxmedical.com
About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of lifecare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels, and hard disk drives. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 36,000 people. For more information, please visit: https://www.hoya.com/en/

View original content:https://www.prnewswire.co.uk/news-releases/hoya-group-company-pentax-of-america-inc-and-magentiq-eye-ltd-announce-their-intention-to-form-a-distribution-partnership-for-the-us-market-302148971.html

Continue Reading

Artificial Intelligence

Pearson augments nursing content with generative AI study tools to improve nursing education and address shortages

Published

on

pearson-augments-nursing-content-with-generative-ai-study-tools-to-improve-nursing-education-and-address-shortages

HOBOKEN, N.J., May 17, 2024 /PRNewswire/ — Pearson (FTSE: PSON.L), the world’s leading learning company, today announced the integration of AI study tools into its Nursing: A Concept-Based Approach to Learning series, the only nursing concepts curriculum built from the ground up as a comprehensive, cohesive learning system.

Pearson’s AI study tools combine the power of generative AI technology with trusted Pearson content to provide scaffolded, guided help when students are stuck on homework problems, and personalized explanations, summaries, and practice problems for more efficient studying.
“Integrating AI study tools into our concept-based nursing series enhances the learning experience, giving nursing students and nurse educators the resources they need to efficiently study and master course concepts,” said Anne Fahlgren, GM of Pearson’s professional portfolio. “This technology will help more nursing candidates prepare for and enter the workforce, while also giving nurse educators the means to scale their teaching further, addressing major challenges in nursing education and society.”
The AI study tools beta will be available both in Pearson+ eTextbook and the accompanying MyLab Nursing course in time for Fall 2024. MyLab is an interactive teaching and learning platform, backed by content from Pearson authors. The platform, with integrated eTextbook, allows instructors to design their course, assign homework and assessments, and monitor student progress in real time.
The US is experiencing shortages of nurses and nurse educators. The National Academy of Medicine’s 2021 report on The Future of Nursing: 2020-2030 notes that, in order to provide sufficient care for an aging population over the next decade, a substantial increase in the nursing workforce will be needed that can practice “in community-based settings with diverse populations that face a variety of lived experiences.” The NAM’s report also references hundreds of nursing faculty position vacancies that have contributed to tens of thousands of qualified applicants being turned away from nursing school admission due to the inability to adequately meet student demand.
Concept-based nursing curriculum is designed to focus on key concepts emphasizing a holistic understanding of nursing principles that can be applied across different patient populations, healthcare settings, and situations. This approach strengthens clinical reasoning skills in the course of patient care. Incorporating generative AI tools into Pearson’s concept-based nursing content supports nurse educators in scaling their teaching and students’ ability to study more efficiently.
Dr. Michelle Aebersold, University of Michigan School of Nursing Clinical Professor and contributor to Nursing: A Concept-Based Approach to Learning, said “Technological advancements like generative AI are transforming the nursing profession. The ability to adapt in a rapidly changing environment is a critical healthcare skill, whether it’s in the course of patient care or in preparing our future nurses for the workforce. The ability of the AI study tools to provide a more user-centered, customized experience is a huge benefit for our students. I’m glad they will have access to Pearson’s AI tools that accommodate the variety of ways students learn and provide personalized support in the moment students need it most. This is the future of individualized learning.”
A Fall 2023 survey of students using Pearson’s AI study tools beta showed strong levels of engagement, with 75% of respondents saying the tools were helpful or very helpful to their studies.
The inclusion of generative AI study tools further solidifies Pearson’s dedication to providing the most comprehensive and effective learning and teaching resources for nursing students and nurse educators across the US. Pearson’s AI study tools are already available in more than 30 Pearson Mastering titles and are set to be integrated into more than 40 Pearson+ eTextbooks and MyLab and Mastering titles across math, science, business, and nursing for August of 2024.
Pearson is committed to investing in the responsible application of AI to advance product innovation and enhance the learning experience to educate, certify, and credential students and the workforce.
Pearson product experts are available to demo the AI study tools for members of the media. Please request demonstrations with the media contact below.
About Pearson
At Pearson, our purpose is simple: to add life to a lifetime of learning. We believe that every learning opportunity is a chance for a personal breakthrough. That’s why our c. 18,000 Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world’s leading learning company, serving customers in nearly 200 countries with digital content, assessments, qualifications, and data. For us, learning isn’t just what we do. It’s who we are. Visit us at pearsonplc.com.
Media [email protected]
Logo – https://mma.prnewswire.com/media/617186/Pearson_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/pearson-augments-nursing-content-with-generative-ai-study-tools-to-improve-nursing-education-and-address-shortages-302147855.html

Continue Reading

Trending